Hyderabad-based drug firm Suven Life Sciences Limited has secured five product patents for their new chemical entities (NCEs) in China & Korea for the treatment of disorders associated with neurodegenerative diseases like Alzheimer's disease, attention deficient hyperactivity disorder, huntington's disease, parkinson and schizophrenia.
These patents are valid through 2007 and 2028 respectively, the company said in a filing to the Bombay Stock Exchange (BSE). It includes three patents from China and two from Korea, and takes the total number to eight patents from China and ten from Korea so far.
Products out of these inventions through internal discovery research efforts may be out-licensed at various phases of clinical development like phase I and phase II, the release said.
Suven has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage under its portfolio.
The company's scrip is currently trading at Rs 34.10 on BSE, up 3.02% over the previous close of Rs 33.11.
